Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome-Reference-Cited by-同舟云学术

Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome

Published:2015-05-25 Issue:6 Volume:67 Page:1623-1628
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Jousse-Joulin Sandrine¹,Devauchelle-Pensec Valérie¹,Cornec Divi¹,Marhadour Thierry²,Bressollette Luc²,Gestin Simon²,Pers Jacques Olivier³,Nowak Emmanuel⁴,Saraux Alain¹

Affiliation:

1. CHU de la Cavale Blanche and EA 2216, INSERM ESPRI, ERI29 Université Bretagne Occidentale; Brest France

2. CHU de la Cavale Blanche Brest; France

3. EA 2216, INSERM ESPRI, ERI29 Université Bretagne Occidentale; Brest France

4. INSERM CIC 0502, CHU de la Cavale Blanche; Brest France

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Reference16 articles.

1. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study;Pijpe;Arthritis Rheum,2005

2. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study;Dass;Ann Rheum Dis,2008

3. Treatment of primary Sjögren's syndrome with rituximab: a randomized trial;Devauchelle-Pensec;Ann Intern Med,2014

4. Treatment of primary Sjögren syndrome with rituximab;Saraux;Ann Intern Med,2014

5. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?;Galarza;Clin Rev Allergy Immunol,2008

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Connecting salivary gland inflammation to specific symptoms in Sjögren’s disease;Expert Review of Clinical Immunology;2024-07-21

2. Clinical and laboratory characteristics of salivary gland ultrasonography‐positive patients with primary Sjögren's syndrome;Oral Diseases;2024-07-05

3. A case report of AQP4-IgG-seropositive refractory neuromyelitis optica spectrum disorder patient with Sjögren’s syndrome and pancytopenia treated with inebilizumab;Frontiers in Neurology;2024-06-05

4. Treatment of non-systemic Sjögren's syndrome: Potential prevention of systematization with immunosuppressant agent/biotherapy;Journal of Translational Autoimmunity;2024-06

5. Identification of outcome domains in primary Sjögren's disease: A scoping review by the OMERACT Sjögren disease working group;Seminars in Arthritis and Rheumatism;2024-04